...
首页> 外文期刊>Angiology: the Journal of Vascular Diseases >Oxerutins (Venoruton): efficacy in chronic venous insufficiency--a double-blind, randomized, controlled study.
【24h】

Oxerutins (Venoruton): efficacy in chronic venous insufficiency--a double-blind, randomized, controlled study.

机译:Oxerutins(Venoruton):在慢性静脉功能不全中的功效-一项双盲,随机对照研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The aim of this study was to confirm the clinical efficacy of oxerutins by evaluation of venous parietal tone and microvascular perfusion in a double-blind, randomized, placebo-controlled study. The study included 60 patients. Venous tone was evaluated by air-plethysmography (APG) in patients with venous insufficiency (CVI). Forty patients were treated with oxerutins and 20 with placebo for 4 weeks. The dose of the first 2 weeks was higher than that of the following 2 weeks. The age range was between 18 and 65 years. Randomized patients received treatment (oxerutins or placebo) according to the grade of CVI. Patients with grade I CVI received 2 g/day in the first 2 weeks of treatment and 1 g/day in the following weeks. Patients with grade II CVI received 3 g/day in the first 2 weeks and 2 g/day in the following 2 weeks. Visits were scheduled at baseline time (visit 1), at 2 weeks (visit 2) and at 4 weeks (visit 3). They were assessed with the following: (1) APG; (2) light reflection rheography (LRR); (3) capillaroscopy; (4) liquid crystals thermography. CVI signs/symptoms--heavy legs, edema, paresthesia, and cramps--were evaluated following a 4-point rating scale (0 = no symptom; 3 = severe symptoms). At visit 3 a final opinion on efficacy was provided by both patients and investigators, based on a 4-point scale (none, fairly good, good, excellent). The two groups were homogeneous for age, sex, and clinical distribution. The changes in venous capacity, were significant (p<0.01) in the oxerutins group at visits 2 and 3; values in the placebo group remained unchanged. The changes in LRR were significant in the treatment group at visits 2 (p<0.05) and 3 (p<0.01); values in the placebo group remained unchanged. Changes in temperature were significant in the oxerutins group at visits 2 (p<0.05) and 3 (p<0.01); changes in the placebo group were not significant at the end of the study. Capillaroscopy showed an improvement in patients treated with oxerutins. The results of the analysis of signs/symptoms favored active treatment. The overall effects of oxerutins were significantly better than the effects of placebo. Considering both noninvasive tests and clinical evaluation, oxerutins is effective in controlling chronic venous hypertension, without side effect, and with good tolerability.
机译:这项研究的目的是通过在双盲,随机,安慰剂对照研究中评估静脉壁顶张力和微血管灌注来确定氧氟沙星的临床疗效。该研究包括60名患者。通过空气体积描记法(APG)评估静脉功能不全(CVI)患者的静脉张力。 40例患者接受了奥曲汀治疗,20例接受了安慰剂治疗4周。前2周的剂量高于后2周的剂量。年龄范围是18至65岁。随机分组的患者根据CVI的等级接受治疗(奥曲汀或安慰剂)。 I CVI级患者在治疗的前2周/天接受2 g /天,随后几周接受1 g /天。 II级CVI患者在前2周每天接受3 g /天,随后2周每天接受2 g /天。探访安排在基线时间(第1次访问),第2周(第2次访问)和第4周(第3次访问)进行。对他们进行了以下评估:(1)APG; (2)光反射流变术(LRR); (3)毛细管镜检查; (4)液晶热成像。 CVI体征/症状-重腿,浮肿,感觉异常和抽筋-按照4分制评分标准进行评估(0 =无症状; 3 =严重症状)。在第3次就诊时,患者和研究者均基于4分制(无,相当好,好,优秀)对疗效提出了最终意见。两组在年龄,性别和临床分布方面均相同。在第2次和第3次就诊时,奥沙菌素组的静脉容量变化显着(p <0.01);安慰剂组的数值保持不变。治疗组LRR的变化在第2次访视(p <0.05)和第3次访视(p <0.01)有显着性;安慰剂组的数值保持不变。在第2次访视(p <0.05)和第3次访视(p <0.01)时,奥曲霉素组的温度变化明显。在研究结束时,安慰剂组的变化不明显。毛细血管镜检查显示,用氧皮蛋白治疗的患者有所改善。体征/症状的分析结果有利于积极治疗。氧化苦参素的总体效果明显好于安慰剂。考虑到无创性测试和临床评估,奥曲霉素可有效控制慢性静脉高压,无副作用,且具有良好的耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号